Atea insider exercises options for 60,000 shares

Atea Pharmaceuticals, Inc. officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at an exercise price of $1.2400 per share.

Rhea-AI Filing Summary

Atea Pharmaceuticals, Inc. officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at an exercise price of $1.2400 per share. The option was fully vested and exercisable. Following the transaction, she directly holds 823,576 shares of Atea common stock.

Insights

Equity compensation analyst

Routine option exercise increases insider’s direct share ownership with no share sales.

Andrea Corcoran exercised a fully vested stock option for 60,000 shares of Atea Pharmaceuticals common stock at $1.2400 per share. The transaction is coded as an option exercise (M), not an open‑market purchase or sale, and represents a typical compensation-related event.

After the exercise, Corcoran’s option position from this grant is reduced to zero while her direct common stock holdings rise to 823,576 shares. With no reported same-day sales or tax-withholding dispositions, this is an exercise-and-hold pattern, generally viewed as a routine alignment of compensation with equity.

Insider Trade Summary

60,000 shares exercised/converted

Exercise 2 txns

Insider Corcoran Andrea

Role See Remarks

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	60,000	$0.00	$0.00
Exercise	Common Stock	60,000	$1.24	$74K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 823,576 shares (Direct)

Footnotes (1)

1. F1. The option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corcoran Andrea

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M		60,000	A	$1.24	823,576	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.24	03/11/2026		M		60,000		(1)	12/08/2026	Common Stock	60,000	$0	0	D

Explanation of Responses:

1. The option is fully vested and exercisable.

Remarks:

Chief Financial Officer, Executive Vice President, Legal and Secretary

	/s/ Andrea Corcoran	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.